How to Get Jatenzo in New Mexico

Jatenzo: What New Mexico Patients Need to Know

Jatenzo is the first FDA-approved oral testosterone undecanoate capsule for adult males with hypogonadism due to certain medical conditions. The FDA approved Jatenzo in March 2019 specifically for men whose bodies do not produce adequate testosterone because of genetic problems, chemotherapy, or structural damage to the hypothalamus, pituitary, or testes.

Unlike injectable testosterone cypionate or topical gels, Jatenzo bypasses first-pass liver metabolism through its lymphatic absorption pathway. The capsule is taken twice daily with food. In the key trial by Swerdloff et al. (2020), 87% of men treated with oral testosterone undecanoate achieved serum testosterone within the normal range (300 to 1 to 100 ng/dL) by day 90, with a mean Cavg of 489 ng/dL at the 237 mg twice-daily dose.

For New Mexico residents, accessing Jatenzo involves confirming a clinical diagnosis of hypogonadism, selecting a licensed prescriber (in-person or telehealth), completing required bloodwork, and navigating insurance or cash-pay pharmacy options.

Who Can Prescribe Jatenzo in New Mexico

Any clinician holding an active New Mexico medical license and valid DEA registration can prescribe Jatenzo. This includes physicians (MD/DO), nurse practitioners (NP), and physician assistants (PA). New Mexico grants NPs full practice authority under the Nursing Practice Act, meaning NPs can independently diagnose hypogonadism, order confirmatory labs, and prescribe Schedule III controlled substances like testosterone without physician oversight.

PAs in New Mexico prescribe under a collaborative practice agreement, though the supervising physician does not need to co-sign each testosterone prescription individually. The critical requirement is that the prescriber hold a current New Mexico Controlled Substance Registration in addition to their DEA number.

Endocrinologists and urologists most commonly manage testosterone therapy, but primary care physicians, sports medicine doctors, and men's health specialists also prescribe Jatenzo routinely. The Endocrine Society's 2018 clinical practice guideline recommends testosterone treatment for men with symptomatic hypogonadism confirmed by at least two morning serum testosterone measurements below 300 ng/dL.

Telehealth Access to Jatenzo in New Mexico

New Mexico permits testosterone prescribing via telehealth with no in-person visit requirement for initial consultation. The state's telehealth parity laws allow synchronous audio-video consultations to establish a provider-patient relationship sufficient for prescribing controlled substances.

A typical telehealth pathway for Jatenzo in New Mexico follows this sequence:

1. Complete an online intake questionnaire covering symptoms (fatigue, low libido, reduced muscle mass, mood changes) and medical history
2. Obtain lab work at a local draw site (Quest Diagnostics and Labcorp both operate in Albuquerque, Las Cruces, Santa Fe, and Rio Rancho)
3. Attend a synchronous video consultation with a licensed prescriber
4. Receive an electronic prescription sent to a specialty or retail pharmacy
5. Begin therapy with a follow-up lab check at 4 to 6 weeks

Telehealth platforms prescribing Jatenzo must ensure their clinicians hold active New Mexico licenses. The prescriber does not need to be physically located in New Mexico at the time of consultation, but must be licensed there. Prescriptions can be transmitted electronically to any pharmacy licensed to dispense in the state, including out-of-state mail-order pharmacies registered with the New Mexico Board of Pharmacy.

Required Labs Before Starting Jatenzo in New Mexico

The Endocrine Society guideline and American Urological Association (2018) both require biochemical confirmation before initiating testosterone therapy. New Mexico prescribers follow these same evidence-based protocols.

Mandatory pre-treatment labs include:

• Two morning total testosterone levels (drawn between 7:00 AM and 10:00 AM, fasting preferred), both below 300 ng/dL
• Complete blood count (CBC) with hematocrit baseline
• Comprehensive metabolic panel
• Lipid panel (total cholesterol, LDL, HDL, triglycerides)
• PSA (prostate-specific antigen) for men aged 40 and older

Additional labs ordered at clinical discretion:

• Free testosterone or bioavailable testosterone (useful when SHBG is suspected to be abnormal)
• LH and FSH (to distinguish primary from secondary hypogonadism)
• Prolactin (to rule out pituitary adenoma in secondary hypogonadism)
• Estradiol
• Hemoglobin A1c or fasting glucose

Jatenzo carries a specific FDA boxed warning regarding blood pressure elevation. The Swerdloff et al. trial reported that 4.9% of men on oral TU experienced systolic blood pressure increases above 140 mmHg, compared to 2.8% at baseline. Prescribers in New Mexico should document baseline blood pressure and may require ambulatory monitoring in patients with pre-existing hypertension.

Hematocrit monitoring is also required during therapy. The Endocrine Society recommends checking hematocrit at 3 to 6 months, then annually. If hematocrit exceeds 54%, the guideline recommends dose reduction or therapy discontinuation.

New Mexico Pharmacy Options for Jatenzo

Jatenzo is dispensed at retail pharmacies, specialty pharmacies, and through mail-order services. Brand Jatenzo carries a wholesale acquisition cost of approximately $580 to $650 per month without insurance.

Retail pharmacy access: CVS, Walgreens, and Albertsons pharmacies across New Mexico stock or can order Jatenzo within 2 to 3 business days. Large-volume locations in Albuquerque and Las Cruces typically maintain inventory.

Specialty pharmacy: Some insurers require Jatenzo to be dispensed through a designated specialty pharmacy. Accredo, AllianceRx Walgreens Prime, and OptumRx Specialty are common payers' preferred networks. These ship directly to the patient's address in New Mexico, usually arriving within 3 to 5 business days after prior authorization approval.

503A compounding pharmacies: New Mexico licenses 503A compounding pharmacies that can prepare oral testosterone undecanoate capsules as a patient-specific compound. This option may reduce cost (typically $80 to $200 per month) but uses a compounded formulation rather than the branded Jatenzo product. The New Mexico Board of Pharmacy regulates these facilities under state compounding rules aligned with USP 795 standards. Compounded oral TU is not FDA-approved and lacks the specific lymphatic-absorption formulation of Jatenzo. Patients choosing this route should discuss bioavailability differences with their prescriber.

Manufacturer savings program: Tolmar offers a co-pay assistance card for commercially insured patients that can reduce out-of-pocket costs to $0 to $75 per month. This card does not apply to government insurance (Medicaid, Medicare, Tricare, VA).

Insurance Coverage and Prior Authorization in New Mexico

New Mexico Medicaid (Centennial Care 2.0) does not cover brand-name Jatenzo on its preferred drug list. Patients on Medicaid seeking oral testosterone replacement would need to either appeal for an exception (rarely granted for Jatenzo given injectable alternatives on formulary) or pursue cash-pay/compounded options.

Commercial insurers in New Mexico (Blue Cross Blue Shield of NM, Presbyterian Health Plan, Western Sky Community Care, Molina) generally cover Jatenzo as a non-preferred brand with prior authorization. The PA process requires documentation of:

• Confirmed diagnosis of male hypogonadism (ICD-10 E29.1)
• Two morning serum testosterone levels below 300 ng/dL
• Clinical symptoms consistent with testosterone deficiency
• A stated reason why injectable or topical testosterone is not appropriate (injection phobia, skin transfer risk, adherence concerns, site reactions)
• Prescriber's NPI and DEA numbers

Presbyterian Health Plan's current formulary places Jatenzo at Tier 3 (non-preferred brand) with a $75 to $150 copay after prior authorization. BCBS of New Mexico requires step therapy showing failure of or contraindication to at least one topical testosterone product before approving Jatenzo.

PA turnaround in New Mexico averages 3 to 7 business days for commercial plans. Urgent requests (defined as situations where delay could cause serious health consequences) must be resolved within 24 hours per state insurance regulations.

Transferring a Jatenzo Prescription to New Mexico

Patients relocating to New Mexico can transfer an existing Jatenzo prescription from another state. New Mexico Board of Pharmacy regulations permit controlled substance prescription transfers between pharmacies, with the following conditions:

• The transfer must occur directly between licensed pharmacists (phone, fax, or electronic transfer)
• Schedule III prescriptions may be transferred once, with remaining refills honored
• The receiving New Mexico pharmacy must verify the original prescription's validity

If the prescription has no remaining refills, the patient's new NM-licensed provider can issue a new prescription based on existing medical records. Most telehealth platforms support this by obtaining records from the previous provider and conducting a brief re-evaluation visit. The process typically takes 3 to 5 business days from records receipt to new prescription issuance.

Patients should request their most recent lab results (total testosterone, hematocrit, PSA) from their prior provider to avoid redundant testing. Labs performed within the prior 3 months are generally accepted by New Mexico clinicians.

Timeline: From Consultation to First Dose

The total elapsed time from initial inquiry to taking your first Jatenzo capsule in New Mexico typically spans 5 to 14 days, depending on lab turnaround and insurance status.

Day 1 to 2: Complete intake form and schedule lab draw. Many platforms offer same-day or next-day lab appointments at Quest or Labcorp locations in Albuquerque, Santa Fe, Las Cruces, and Rio Rancho.

Day 2 to 4: Lab results return (Quest averages 24 to 48 hours for hormone panels). Schedule video consultation.

Day 3 to 5: Synchronous telehealth visit. If diagnosis is confirmed, electronic prescription transmitted same day.

Day 4 to 7 (cash pay): Pharmacy fills and ships or patient picks up locally. No PA needed.

Day 7 to 14 (insured with PA): Prior authorization submitted, approved, specialty or retail pharmacy fills and ships.

Cash-pay patients using local retail pharmacies can sometimes obtain Jatenzo within 48 hours of prescription transmission if the pharmacy has stock.

Jatenzo Dosing and Monitoring for New Mexico Patients

The FDA-approved prescribing information specifies starting Jatenzo at 237 mg twice daily with food. After approximately 1 month, the prescriber checks a serum total testosterone level (drawn 6 hours post-dose to approximate Cavg) and adjusts the dose:

• If testosterone is above 1 to 100 ng/dL: decrease to 198 mg twice daily
• If testosterone remains above 1 to 100 ng/dL at 198 mg: decrease to 158 mg twice daily
• If testosterone is still above 1 to 100 ng/dL at 158 mg: discontinue Jatenzo

In the Swerdloff et al. registration trial, 87.3% of subjects achieved testosterone Cavg between 300 and 1 to 100 ng/dL. The most common dose at steady state was 237 mg twice daily (used by 55% of participants), followed by 198 mg twice daily (25%).

Follow-up monitoring per Endocrine Society recommendations includes:

• Total testosterone at 1 month, 3 months, then every 6 to 12 months
• Hematocrit at 3 months, 6 months, then annually
• Lipid panel annually
• PSA at 3 to 6 months, then per USPSTF screening guidelines
• Blood pressure at each visit

New Mexico telehealth providers can order follow-up labs through the same local draw sites used for initial testing. Results transmit electronically to the prescriber for dose adjustments without requiring an additional video visit in most cases.

Cost Comparison: Brand Jatenzo vs. Compounded Oral TU in New Mexico

| Option | Monthly Cost | Notes | |--------|-------------|-------| | Brand Jatenzo (cash) | $580 to $650 | Retail price without insurance | | Brand Jatenzo (with copay card) | $0 to $75 | Commercial insurance only | | Brand Jatenzo (insured, Tier 3) | $75 to $150 | After PA approval | | Compounded oral TU (503A) | $80 to $200 | Not bioequivalent to Jatenzo | | Injectable testosterone cypionate | $30 to $80 | For cost comparison only |

The price gap between brand Jatenzo and compounded oral TU is significant. Patients should weigh the FDA-approved formulation's documented lymphatic absorption pathway and pharmacokinetic profile against cost savings from compounding. The Swerdloff trial specifically used the Jatenzo SEDDS (self-emulsifying drug delivery system) formulation. Compounded oral TU in oil-filled capsules may not achieve equivalent bioavailability.

Contraindications and Safety Monitoring Specific to New Mexico Practice

The FDA label for Jatenzo includes a REMS (Risk Evaluation and Mitigation Strategy) focused on cardiovascular monitoring, specifically the potential for blood pressure increases. The TRAVERSE trial (NEJM 2023, N=5,204) provided reassuring data on cardiovascular safety of testosterone therapy broadly, showing non-inferiority to placebo for major adverse cardiovascular events (HR 0.99 to 95% CI 0.81 to 1.21).

Absolute contraindications to Jatenzo include:

• Breast or prostate cancer (known or suspected)
• Polycythemia (hematocrit above 48% at baseline per some guidelines, above 50% per others)
• Untreated severe obstructive sleep apnea
• Uncontrolled heart failure
• Desire for fertility within the next 12 months (exogenous testosterone suppresses spermatogenesis)
• Women and children (Jatenzo is approved only for adult men)

New Mexico prescribers should note that at altitude (Santa Fe sits at 7,199 feet, Albuquerque at 5,312 feet), baseline hematocrit values run 1 to 3 points higher than sea-level norms. A patient with a baseline hematocrit of 50% at Santa Fe altitude requires closer monitoring but is not necessarily contraindicated, according to published altitude-adjusted hematocrit references. The decision to initiate therapy at borderline hematocrit values should account for altitude-adjusted norms.